News of biotechnologies
InfoWeb MarketplaceThe trial continues as originally planned, following the first meeting of the Monitoring and Monitoring Committee (DSMB - Data and Safety Monitoring Board).Genticel, a French biotechnology company specializing in the development of therapeutic vaccines, today announced that it has already recruited half the patients in its RHEIA-VAC Phase II study, in full compliance with the company's projections. The 39 research sites in seven European countries (Germany, Belgium, Spain, Finland, France, the Netherlands and the United Kingdom) are actively participating in this clinical trial. In addition, the "Data and Safety Monitoring Board" (DSMB),…Genticel: 50% of patients recruited for the ProCervix Phase II StudyRead more
InfoWeb MarketplaceJennerex, Inc., an American biotechnology company specializing in the development of innovative targeted oncolytic products in the field of cancer, and Transgene (NYSE Euronext Paris: FR0005175080), an integrated biotechnology company specializing in the development of immunotherapy products, Treatment of patients enrolled in a Phase Ib trial with JX-594 in metastatic colorectal cancer ("mCRC") was initiated. The study will be conducted in South Korea, the country for which the rights to the product have been dismissed from Green Cross Corporation. "The start of this study marks an important milestone in the development of JX-594 in a second…Jennerex and Transgene announce initiation of clinical trial in metastatic colon cancer with intravenous JX-594Read more
InfoWeb MarketplaceNovasep Process, a bioprocess division of Novasep, a leading innovator in purification technologies for the life sciences industries, and Danisco, the world leader in food ingredients, enzymes and biotechnology solutions , Today announce the industrialization of an innovative process for the production of natural betaine. The production unit will be the first to use this new process for the extraction of vinasse, a by-product of the production of bioethanol from sugar beet. This new process will allow Danisco to significantly increase the quantity of natural betaine available on the market, a commodity commonly used in animal feed and…Novasep and Danisco develop the first process for the industrial production of betaine from a by-product of bioethanolRead more
InfoWeb MarketplaceDeinove, Young Innovative Enterprise (JEI) dedicated to biotechnologyResearch and development of innovative processes for the production of biofuels, announced today that it has received ? 6 million from OSEO under the Industrial Strategic Innovation (ISI) program for the implementation of the project Deinol.Deinove is the leader of the Deinol consortium, which also includes a leading industrial producer of ethanol in Europe, as well as two academic partners, CPBS (CNRS University of Montpellier 1) and LISBP (INSA Toulouse / CNRS / INRA ).The objective of the Deinol project is to open the way to the production of lignocellulosic ethanol (2nd…Deinove, Young Innovative Company specializing in biofuels, receives ? 6 million from OSEORead more
InfoWeb MarketplaceCellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis S.A. (Alternext: ALCLS), today marketed cGPS® CHO-S CEMAX®, which enables targeted integration into suspended cells. By reducing the time required to obtain the clones and by making it possible to obtain a very good stability of production over time, this kit represents a real step forward in the production of recombinant proteins and monoclonal antibodies. The production of antibodies for research and diagnosis will be facilitated.The culture of cells in suspension makes it possible to obtain a volume and a cell concentration well above the culture of…Cellectis bioresearch launches cGPS® CHO-S CEMAX®Read more
InfoWeb MarketplaceAriana (TM) Pharma, a provider of decision support tools for optimizing drug discovery, today announced funding of ? 1 million from OSEO, within the framework of the IMAkinib program, Which aims at the development of biomarkers in oncology. This collaborative program will enable Ariana (TM) to significantly strengthen its KEM (Knowledge Extraction Management) technology by working on a new area: the development of imaging biomarkers.Cancer remains a very prominent pathology, in terms of incidence, mortality and associated costs. The WHO estimates that cancer-related mortality is expected to increase by 51 percent between 2002 and 2030, with…Ariana (TM) Pharma receives 1 million Euros from OSEO under the ISI program IMAkinibRead more
InfoWeb MarketplaceBioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment of cancer and AIDS and supportive care, presented at the 49th Annual Conference of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Held in San Francisco from September 12 to 15, the results of three Phase III trials with miconazole Lauriad® and data on its integrase inhibitor.The results of the Phase III trial with LoramycTM (miconazole Lauriad®), an oral mucoadhesive gingival tablet, demonstrate the efficacy of Lauriad® miconazole not lower than that of the US reference comparator (clotrimazole pellets) in Oropharyngeal candidiasis (COP)…Presentations by BioAlliance Pharma at the 49th Annual ICAAC Conference on Results of Three Phase III Trials with LoramycTMRead more